{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:36:45Z","timestamp":1789501005631,"version":"build-2803163510"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Eye Research"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.exer.2020.108020","type":"journal-article","created":{"date-parts":[[2020,3,21]],"date-time":"2020-03-21T11:11:02Z","timestamp":1584789062000},"page":"108020","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Intravitreal bromfenac liposomal suspension (100\u00a0\u03bcg \/ 0.1\u00a0ml). A safety study in rabbit eyes"],"prefix":"10.1016","volume":"194","author":[{"given":"Idaira","family":"S\u00e1nchez-Santos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo A.","family":"Garc\u00eda-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Gonzalez-Salinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica Anayatzin","family":"Linares-Alba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abelardo A.","family":"Rodr\u00edguez-Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Garc\u00eda-Santisteban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Tirado-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Hern\u00e1ndez-Pi\u00f1amora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Garc\u00eda-Arzate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virgilio","family":"Morales-Cant\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Quiroz-Mercado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.exer.2020.108020_bib1","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/IAE.0b013e3181a2f42a","article-title":"Preparation, characterization, and in vivo evaluation of nanoliposomes-encapsulated bevacizumab (avastin) for intravitreal administration","volume":"29","author":"Abrishami","year":"2009","journal-title":"Retina"},{"key":"10.1016\/j.exer.2020.108020_bib2","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0014-2999(02)02793-0","article-title":"Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model","volume":"458","author":"Ayalasomayajula","year":"2003","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.exer.2020.108020_bib3","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jconrel.2012.01.019","article-title":"Liposomes for intravitreal drug delivery: a state of the art","volume":"161","author":"Bochot","year":"2012","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.exer.2020.108020_bib4","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ajo.2016.04.017","article-title":"Pro-permeability factors in diabetic macular edema; the diabetic macular edema treated with ozurdex trial","volume":"168","author":"Campochiaro","year":"2016","journal-title":"Am. J. Ophthalmol."},{"issue":"4","key":"10.1016\/j.exer.2020.108020_bib5","first-page":"136","article-title":"Surgical versus medical treatment for diabetic macular edema: a review","volume":"6","author":"Crim","year":"2017","journal-title":"Med. Hypothesis, Discov. Innovation (MEHDI) Ophthalmol."},{"key":"10.1016\/j.exer.2020.108020_bib6","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0169-409X(89)90024-0","article-title":"Generating and loading of liposomal systems for drug-delivery applications","volume":"3","author":"Cullis","year":"1989","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.exer.2020.108020_bib7","first-page":"R735","article-title":"Interaction between NO and COX pathways in retinal cells exposed to elevated glucose and retina of diabetic rats","volume":"287","author":"Du","year":"2004","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.exer.2020.108020_bib9","first-page":"343","article-title":"High-mobility group box-1 and biomarkers of inflammation in the vitreous from patients with proliferative diabetic retinopathy","volume":"30","author":"El-Asrar","year":"2011","journal-title":"Mol. Vis."},{"key":"10.1016\/j.exer.2020.108020_bib10","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1097\/IAE.0b013e31822a042a","article-title":"Intravitreal diclofenac versus intravitreal triamcinolone acetonide in the treatment of diabetic macular edema","volume":"31","author":"Elbendary","year":"2011","journal-title":"Retina"},{"key":"10.1016\/j.exer.2020.108020_bib11","doi-asserted-by":"crossref","first-page":"132","DOI":"10.4274\/tjo.32458","article-title":"Ocular drug, gene and cellular delivery systems and advanced therapy medicinal products","volume":"48","author":"Eldem","year":"2018","journal-title":"Turk. J. Ophthalmol."},{"key":"10.1016\/j.exer.2020.108020_bib12","first-page":"1796","article-title":"Photocoagulation for diabetic macular edema","volume":"103","year":"1985","journal-title":"ETDRS Study report No.1 Arch. Ophthalmol."},{"issue":"3","key":"10.1016\/j.exer.2020.108020_bib13","first-page":"67","article-title":"Comparison of intravitreal bevacizumab and intravitreal diclofenac in the treatment of diabetic macular edema: a 6-month follow-up","volume":"6","author":"Faghihi","year":"2017","journal-title":"Med. Hypothesis Innov.ETDRS Study report No.1 Arch. Ophthalmol. Ophthalmol."},{"key":"10.1016\/j.exer.2020.108020_bib14","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1159\/000071373","article-title":"Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis","volume":"37","author":"Gately","year":"2003","journal-title":"Prog. Exp. Tumor Res."},{"key":"10.1016\/j.exer.2020.108020_bib15","series-title":"Antigen Delivery Systems: Immunological and Technological Issues","first-page":"101","article-title":"Virosomes, a new liposome-like vaccine delivery system","author":"Gl\u00fcck","year":"1997"},{"key":"10.1016\/j.exer.2020.108020_bib16","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ajo.2016.09.012","article-title":"Early and long-term responses to anti-vascular endothelial growth factor therapy in diabetic macular edema: analysis of protocol I data","volume":"172","author":"Gonzalez","year":"2016","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.exer.2020.108020_bib17","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.jfo.2014.03.001","article-title":"\u00c9tude r\u00e9trospective du traitement par Ozurdex\u00ae dans l\u2019\u0153d\u00e8me maculaire diab\u00e9tique : MOZART study","volume":"37","author":"Guigou","year":"2014","journal-title":"J. Fr. Ophthalmol."},{"key":"10.1016\/j.exer.2020.108020_bib18","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1007\/s00125-010-1836-3","article-title":"Prevalence and healthcare costs of diabetic retinopathy: a population-based register study in Sweden","volume":"53","author":"Heintz","year":"2010","journal-title":"Diabetologia"},{"key":"10.1016\/j.exer.2020.108020_bib19","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1096\/fj.01-0707fje","article-title":"Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression","volume":"16","author":"Joussen","year":"2002","journal-title":"Faseb. J."},{"issue":"3","key":"10.1016\/j.exer.2020.108020_bib20","doi-asserted-by":"crossref","first-page":"e355","DOI":"10.1111\/aos.13604","article-title":"Intravitreal diclofenac for treatment of refractory uveitis-associated cystoid macular oedema: a before and after clinical study","volume":"96","author":"Kianersi","year":"2018","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.exer.2020.108020_bib21","series-title":"Proceedings of the American Society of Cataract and Refractive Surgery","article-title":"Evaluation of the human Cox-2 inhibition of amfenac, bromfenac, diclofenac and ketorolac","author":"Kida","year":"2007"},{"key":"10.1016\/j.exer.2020.108020_bib22","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.ophtha.2010.03.045","article-title":"A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2","volume":"117","author":"Michaelides","year":"2010","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.exer.2020.108020_bib23","doi-asserted-by":"crossref","first-page":"68","DOI":"10.5301\/ejo.5001000","article-title":"Subthreshold micropulse laser reduces anti-VEGF injection burden in patients with diabetic macular edema","volume":"28","author":"Moisseiev","year":"2018","journal-title":"Eur. J. Ophthalmol."},{"key":"10.1016\/j.exer.2020.108020_bib24","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2174\/1568010053622975","article-title":"Inhibition of angiogenesis by non-steroidal anti-inflammatory drugs: from the bench to the bedside and back","volume":"4","author":"Monnier","year":"2005","journal-title":"Curr. Drug Targets - Inflamm. Allergy"},{"issue":"3","key":"10.1016\/j.exer.2020.108020_bib25","doi-asserted-by":"crossref","first-page":"326","DOI":"10.5301\/ejo.5000888","article-title":"Bromfenac eyedrops in the treatment of diabetic macular edema: a pilot study","volume":"27","author":"Pinna","year":"2017","journal-title":"Eur. J. Ophthalmol."},{"key":"10.1016\/j.exer.2020.108020_bib26","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/872978","article-title":"Usefulness of the vitreous fluid analysis in the translational research of diabetic retinopathy","author":"Sim\u00f3-Servat","year":"2012","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.exer.2020.108020_bib27","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s40618-017-0648-4","article-title":"Diabetic retinopathy: new therapeutic perspectives based on pathogenic mechanisms","volume":"40","author":"Sim\u00f3-Servat","year":"2017","journal-title":"J. Endocrinol. Invest."},{"key":"10.1016\/j.exer.2020.108020_bib28","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.ajo.2011.03.033","article-title":"Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema","volume":"152","author":"Sohn","year":"2011","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.exer.2020.108020_bib29","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.preteyeres.2011.05.002","article-title":"Inflammation in diabetic retinopathy","volume":"30","author":"Tang","year":"2011","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.exer.2020.108020_bib30","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.jcrs.2007.05.015","article-title":"In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac and bromfenac","volume":"33","author":"Walters","year":"2007","journal-title":"J. Cataract Refract. Surg."},{"key":"10.1016\/j.exer.2020.108020_bib31","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1185\/030079906X112471","article-title":"Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium","volume":"22","author":"Waterbury","year":"2006","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.exer.2020.108020_bib32","first-page":"3906","article-title":"Combination of Aflibercept and bromfenac therapy in age-related macular degeneration: a pilot study Aflibercept and bromfenac in AMD","volume":"21","author":"Wygl\u0119dowska-Promie\u0144ska","year":"2015","journal-title":"Med. Sci. Mon. Int. Med. J. Exp. Clin. Res."},{"key":"10.1016\/j.exer.2020.108020_bib33","series-title":"Liposome Technology: Liposome Preparation and Related Techniques","article-title":"Immunopotentiating reconstituted influenza virosomes","author":"Zurbriggen","year":"2007"}],"container-title":["Experimental Eye Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014483519308826?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014483519308826?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T05:04:42Z","timestamp":1757999082000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014483519308826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":32,"alternative-id":["S0014483519308826"],"URL":"https:\/\/doi.org\/10.1016\/j.exer.2020.108020","relation":{},"ISSN":["0014-4835"],"issn-type":[{"value":"0014-4835","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravitreal bromfenac liposomal suspension (100\u00a0\u03bcg \/ 0.1\u00a0ml). A safety study in rabbit eyes","name":"articletitle","label":"Article Title"},{"value":"Experimental Eye Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exer.2020.108020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108020"}}